MediWound Ltd - Asset Resilience Ratio
MediWound Ltd (M8W) has an Asset Resilience Ratio of 44.65% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read M8W total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how MediWound Ltd's Asset Resilience Ratio has changed over time. See M8W net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MediWound Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MediWound Ltd (M8W) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €29.68 Million | 44.65% |
| Total Liquid Assets | €29.68 Million | 44.65% |
Asset Resilience Insights
- Very High Liquidity: MediWound Ltd maintains exceptional liquid asset reserves at 44.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MediWound Ltd Industry Peers by Asset Resilience Ratio
Compare MediWound Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for MediWound Ltd (2016–2023)
The table below shows the annual Asset Resilience Ratio data for MediWound Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 44.65% | €29.68 Million ≈ $34.69 Million |
€66.46 Million ≈ $77.70 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€50.02 Million ≈ $58.47 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€19.74 Million ≈ $23.08 Million |
-- |
| 2020-12-31 | 12.95% | €4.02 Million ≈ $4.70 Million |
€31.07 Million ≈ $36.32 Million |
-41.34pp |
| 2019-12-31 | 54.29% | €22.04 Million ≈ $25.76 Million |
€40.59 Million ≈ $47.45 Million |
+6.33pp |
| 2018-12-31 | 47.96% | €16.92 Million ≈ $19.78 Million |
€35.28 Million ≈ $41.24 Million |
-- |
| 2017-12-31 | 0.00% | €0.00 ≈ $0.00 |
€44.13 Million ≈ $51.60 Million |
-- |
| 2016-12-31 | 3.25% | €1.16 Million ≈ $1.36 Million |
€35.76 Million ≈ $41.81 Million |
-- |
About MediWound Ltd
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers an… Read more